STAT

3 China biotech stories to watch in 2019

In 2018, biotech in China generated relentless news. What's next for 2019?

As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here

This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

You're reading a preview, sign up to read more.

More from STAT

STAT6 min readWellness
Opinion: Ebola Vaccine For Pregnant Women: One Step Closer But Still More To Go
Protecting fetuses from harmful exposures is a laudable goal. But pregnancy shouldn't automatically exclude women from receiving lifesaving therapies like the #Ebola vaccine.
STAT2 min readPolitics
Amgen, Merck, And Eli Lilly Sue Over Trump Administration Policy To Require Drug Prices In TV Ads
Amgen, Merck, Eli Lilly, and the Association of National Advertisers sued the Trump administration over a new policy to require drug prices in TV ads.
STAT4 min readSociety
Opinion: Cost-cutting Jeopardizes Many Americans’ Access To Lifesaving Oxygen Therapy
We wouldn't tolerate a pharmacy failing to provide prescribed medication. We shouldn't tolerate companies failing to deliver prescribed oxygen therapy, though it happens all the time.